[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-352709-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-352709-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","bmx-inhibition-overcomes-small-cell-lung-cancer-chemoresistance-by-stabilizing-e2f1-via-erk12-cyclin-d1cdk46-axis","BMX inhibition overcomes small cell lung cancer chemoresistance by stabilizing E2F1 via ERK1/2-Cyclin D1/CDK4/6 axis","","Chemotherapy resistance limits clinical efficacy in small cell lung cancer (SCLC) and demands improved targeted strategies. The study identifies the BMX-E2F1 axis as a key regulator of chemoresistance. BMX phosphorylated E2F1 at Ser332/337 and stabilized it through the ERK1/2–Cyclin D1/CDK4/6 pathway, reducing ubiquitin-proteasome degradation. BMX inhibition or knockdown lowered E2F1 stability, reversed chemoresistance, and sensitized cells to cisplatin. The BMX inhibitor IHMT-15137 synergized with cisplatin to induce cell-cycle arrest, apoptosis, and DNA damage while suppressing migration and invasion in patient-derived models and xenografts with limited toxicity.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/bmx-inhibition-overcomes-small-cell-lung-cancer-chemoresistance-by-stabilizing-e2f1-via-erk12-cyclin-d1cdk46-axis/352709/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/bmx-inhibition-overcomes-small-cell-lung-cancer-chemoresistance-by-stabilizing-e2f1-via-erk12-cyclin-d1cdk46-axis/352709.png","ImageObject",300,407,{"name":42,"@type":43},"Maya Linwood","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",6,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What role does the BMX-E2F1 axis play in SCLC chemoresistance?","Question",{"text":63,"@type":64},"The BMX-E2F1 axis is identified as a pivotal regulator of chemoresistance in SCLC, promoting E2F1 stability and thus resistance. BMX activity increases phosphorylated BMX and E2F1 in SCLC tissues and cells.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does BMX stabilize E2F1 at the signaling level?",{"text":68,"@type":64},"BMX stabilizes E2F1 via the ERK1/2–Cyclin D1/CDK4/6 signaling axis. It phosphorylates E2F1 at Ser332/337 and inhibits its degradation through the ubiquitin-proteasome pathway.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is IHMT-15137 important, and what is its effect with cisplatin?",{"text":72,"@type":64},"IHMT-15137 is a potent and selective BMX inhibitor. In patient-derived cell/organoid models and chemoresistant lines, IHMT-15137 combined with cisplatin synergistically drives cell-cycle arrest, apoptosis, and DNA damage and suppresses migration and invasion, with significant tumor growth inhibition in vivo.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},352709,1790716095,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962084928432,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Signal Transduction [and Targeted Therapy](and Targeted Therapy www.nature.com/sigtrans)[ www.nature.com/sigtrans](and Targeted Therapy www.nature.com/sigtrans)  \nBMX inhibition overcomes small cell lung cancer chemoresistance by stabilizing E2F1 via ERK1/2-Cyclin D1/ CDK4/6 axis  \nTing Wu1,2, Shuang Qi1,3,4, Chenliang Shi1,2, Chao Wu1,2, Qingwang Liu1,3, Chen Hu1,2, Jie Hu1,2,4, Aoli Wang 1,3, Jing Liu1,2,3,4, Ziping Qi 1,3 ✉, Wenchao Wang 1,2,3,4 ✉ and Qingsong Liu 1,2,3,4 ✉  \n\n| | Chemotherapy resistance remains a critical bottleneck limiting its clinical efﬁcacy in small cell lung cancer (SCLC), with its core mechanisms and targeted intervention strategies urgently requiring breakthroughs. Our study revealed that the BMX (bone marrow tyrosine kinase on chromosome X)-E2F1 (E2F transcription factor 1) axis is a pivotal regulator of chemoresistance in SCLC. Synchronous upregulation of phosphorylated BMX (Tyr566) and E2F1 was observed in SCLC tissues and cells. Mechanistically, BMX stabilized E2F1 via the ERK1/2 (extracellular signal-regulated kinase 1/2)-Cyclin D1/CDK4/6 (cyclin-dependent kinase 4/6) signaling axis, phosphorylating E2F1 at Ser332/337 and inhibiting its degradation via the ubiquitin-proteasome pathway. Inhibition or knockdown of BMX reduced E2F1 stability, promoting its degradation and reversing chemoresistance. E2F1 knockdown decreased the expression of genes associated with cell cycle regulation, migration, invasion, and DNA repair, further sensitizing chemoresistant SCLC cells to cisplatin. We also discovered IHMT-15137, a potent and selective BMX inhibitor. In vitro studies using SCLC patient-derived cells (PDCs)/patient-derived organoids (PDOs) and chemoresistant cell lines revealed that IHMT-15137, combined with cisplatin, synergistically induced cell cycle arrest, apoptosis, and DNA damage while suppressing cell migration and invasion. In vivo xenograft models demonstrated that the combination signiﬁcantly inhibited tumor growth without causing signiﬁcant toxicity. Our ﬁndings reveal the molecular mechanisms of SCLC chemoresistance and suggest potential therapeutic | |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  | strategies targeting the BMX-E2F1 axis to overcome this challenge. |  |\n|  |  |  |\n|  |  |  |\n|  | Signal Transduction and Targeted Therapy (2026)11:125 ; [https://doi.org/10.1038/s41392-026-02644-1](https://doi.org/10.1038/s41392-026-02644-1) |  |\n|  |  |  |\n\nINTRODUCTION  \nSmall cell lung cancer (SCLC) is a highly aggressive neuroendocrine carcinoma that accounts for ~15% of all lung cancer cases, and approximately two-thirds of patients present with extensivestage SCLC (ES-SCLC) .1 Unlike non-small cell lung cancer (NSCLC), which has undergone signiﬁcant progress in targeted therapies and immunotherapies, SCLC treatment has remained largely unchanged over the past few decades. Platinum-based chemotherapy (cisplatin or carboplatin) combined with etoposide remains the standard treatment for SCLC. Although this regimen is highly effective in inducing initial remission, relapse is almost inevitable, and recurrent disease is typically resistant to subsequent therapies, resulting in a dismal 5-year survival rate of only~7% .2 Genomic analyses of SCLC have revealed frequent deletions of the tumor-suppressor genes tumor protein p53 (TP53) andretinoblastoma 1 (RB1), yet actionable genetic alterations remain elusive.1 While recent research has identiﬁed distinct biological subtypes of SCLC on the basis of transcription factor expression proﬁles, current clinical treatment approaches remain uniform across all subtypes.3 Although immunotherapy has shown promise in treating various cancers, its efﬁcacy in SCLC remains  \nlimited. The combination of immune checkpoint inhibitors (ICIs) with chemotherapy has only modestly improved survival outcomes for ES-SCLC patients, with a median ove","cbCaic4aqet83B5q","https://ap.wps.com/l/cbCaic4aqet83B5q","pdf",11760262,21,"English","# Introduction\n## Background on SCLC and current therapy\n## Need for more effective treatments\n## E2F1 role in cancer and regulation\n## RB1 loss and E2F1 upregulation in SCLC","[{\"question\":\"What role does the BMX-E2F1 axis play in SCLC chemoresistance?\",\"answer\":\"The BMX-E2F1 axis is identified as a pivotal regulator of chemoresistance in SCLC, promoting E2F1 stability and thus resistance. BMX activity increases phosphorylated BMX and E2F1 in SCLC tissues and cells.\"},{\"question\":\"How does BMX stabilize E2F1 at the signaling level?\",\"answer\":\"BMX stabilizes E2F1 via the ERK1/2–Cyclin D1/CDK4/6 signaling axis. It phosphorylates E2F1 at Ser332/337 and inhibits its degradation through the ubiquitin-proteasome pathway.\"},{\"question\":\"Why is IHMT-15137 important, and what is its effect with cisplatin?\",\"answer\":\"IHMT-15137 is a potent and selective BMX inhibitor. In patient-derived cell/organoid models and chemoresistant lines, IHMT-15137 combined with cisplatin synergistically drives cell-cycle arrest, apoptosis, and DNA damage and suppresses migration and invasion, with significant tumor growth inhibition in vivo.\"}]","BMX inhibition overcomes small cell lung cancer chemoresistance by stabilizing E2F1 via ERK1/2-Cyclin D1/CDK4/6 axis | PDF",1790101060,53,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7fae1f9bc4a3785a7168ffa0fb7eef46.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d4e22b6349e38cc6c66d22fdc9c0a87a.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3883fc765d2d924f7da9aea2f834101f.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/39a9e5d9d561d00bbe1e94b22590b10c.webp",980,1301]